Physician profile
Eric L Intihar
NPI 1396177085
$1,469.76
in general payments reported to CMS, 2019-2025
18 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $35.97 · 2021: $202 · 2022: $249 · 2023: $93.18 · 2024: $150 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $282.79 | 2019-2021 | |
| Amgen INC. | $183.95 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $156.58 | 2022-2025 | Eysuvis |
| Sun Pharmaceutical Industries INC. | $136.64 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $126.94 | 2019-2021 | |
| Allergan, INC. | $125.15 | 2019-2022 | |
| Oyster Point Pharma, INC. | $93.57 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.70 | 2019 | |
| Bausch & Lomb Americas INC. | $59.76 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Eyevance Pharmaceuticals LLC | $35.68 | 2019 | |
| Abbvie INC. | $32.54 | 2025 | |
| Harrow Eye, LLC | $29.22 | 2025 | Vevye |
| Dompe US, INC. | $24.43 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $22.53 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $21.60 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $19.99 | 2023 | |
| Shire North American Group INC | $17.32 | 2019 | |
| Biotissue Holdings INC. | $8.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Intihar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.